315 related articles for article (PubMed ID: 34345970)
1. The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis.
Xie S; Chen J; Xiong G; Li J; Wan J; Liu Y; Xu R; Zhang W
Eur J Clin Pharmacol; 2021 Oct; 77(10):1485-1494. PubMed ID: 34345970
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials.
Li W; Seo J; Kokkinidis DG; Palaiodimos L; Nagraj S; Korompoki E; Milionis H; Doehner W; Lip GYH; Ntaios G
Int J Stroke; 2023 Apr; 18(4):392-399. PubMed ID: 35689348
[TBL] [Abstract][Full Text] [Related]
4. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Xa inhibitors in patients with heart failure and coronary or peripheral artery disease: a systematic review and meta-analysis of randomized controlled trials.
Chen Y; Feng X; Qi C; Zhou L; Sun Y; Gu Z; Li X
Ann Palliat Med; 2021 Jul; 10(7):8082-8093. PubMed ID: 34353093
[TBL] [Abstract][Full Text] [Related]
6. Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials.
Zhang C; Wang N; Shen NN; Kong LC; He J; Wu Y; Feng D; Gu ZC
Thromb Res; 2020 Jun; 190():122-128. PubMed ID: 32361051
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis.
Hua Y; Sun JY; Su Y; Qu Q; Wang HY; Sun W; Kong XQ
Am J Cardiovasc Drugs; 2021 Jan; 21(1):51-61. PubMed ID: 32514866
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
Sharma A; Caldeira D; Razaghizad A; Pinto FJ; van Veldhuisen DJ; Mehra MR; Lam CSP; Cleland J; Anker SD; Greenberg B; Ferreira JP; Zannad F
BMJ Open; 2023 Aug; 13(8):e068865. PubMed ID: 37567750
[TBL] [Abstract][Full Text] [Related]
13. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
Aronow WS; Shamliyan TA
Am J Ther; 2019; 26(6):e679-e703. PubMed ID: 30461433
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
Yuan J
BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
[TBL] [Abstract][Full Text] [Related]
17. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Lane DA; Raichand S; Moore D; Connock M; Fry-Smith A; Fitzmaurice DA;
Health Technol Assess; 2013 Jul; 17(30):1-188. PubMed ID: 23880057
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
Shantsila E; Lip GY
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD003333. PubMed ID: 27629776
[TBL] [Abstract][Full Text] [Related]
19. Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta-analysis.
Xie C; Hang Y; Zhu J; Li C; Jiang B; Zhang Y; Miao L
Clin Cardiol; 2021 Jan; 44(1):20-26. PubMed ID: 33219708
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
